APELLIS PHARMACT.DL-0001 (1JK F) stock market data APIs
€20.5621
0(0%)
as of September 15, 2025
Try our APIs with
free plan!
APELLIS PHARMACT.DL-0001 Financial Data Overview
Price chart is built with
Anychart
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
Prev. Close
20.5621
Open
20.5621
High
20.5621
Low
20.5621
52 wk Range
13.88-33.045
Market Cap
2 567 M
Shares Outstanding
126 M
Revenue
755 M
EPS
-2.72
Beta
0.723
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get APELLIS PHARMACT.DL-0001 data using free add-ons & libraries
Get APELLIS PHARMACT.DL-0001 Fundamental Data
APELLIS PHARMACT.DL-0001 Fundamental data includes:
- Net Revenue: 755 M
- EBITDA: -188 263 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-06-30
- EPS/Forecast: -1.69
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
APELLIS PHARMACT.DL-0001 News
New
When Can We Expect A Profit From Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)?
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Apellis Pharmaceuticals, Inc., a commercia...
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
Apellis Pharmaceuticals, Inc. WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that management will participate in webcast fireside chat...
FDA Approval and Strategic Deals Drive Apellis Pharmaceuticals’ Stock Higher for the Week
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is one of the 11 Best Short-Term Stocks to Invest in. The company’s weekly stock price performance surges following FDA approvals for EMPAVELI, second-qu...
Apellis Pharmaceuticals Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
Apellis Pharmaceuticals (NASDAQ:APLS) Second Quarter 2025 Results Key Financial Results Revenue: US$178.5m (down 11% from 2Q 2024). Net loss: US$42.2m (loss widened by 12% from 2Q 2024). US$0.33 los...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
